Article published on: 25/09/2014 – adnkronos
Philip Hampton, president of Rbs-Royal Bank of Scotland since February 2009, will be the new president of GlaxoSmithKline. hamptons. This was announced by the British pharmaceutical group, explaining that it will join the company's board as a non-executive director from 1 January 2015, from 1 April 2015 he will become vice president and from 1 September non-executive president in place of Christopher Ghent, or even sooner if he is released from other positions in Rbs. In fact, the Scottish bank specifies that Hampton will leave the company during 2015, after a suitable successor has been appointed.
Related news: GlaxoSmithKline Names RBS's Philip Hampton as Chairman THE WALL STREET JOURNAL
Ed.: CEO of GSK is Sir Andrew Philip Witty, 49 years old, and received total compensation of GBP 7,207,000 in the 2014 tax year
